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a  b  s  t  r  a  c  t
Background:  HTLV-1  proviral  load  is  a risk  marker  for  HAM/TSP,  but  it is  insufﬁcient  to  determine  the  dis-
ease outcome.  HTLV-1  Tax  and  HBZ  proteins  have  been  implicated  in  HAM/TSP  pathogenesis  in inducing
cell  proliferation  and  cytotoxic  T lymphocytes  response.
Objectives:  To  quantify  the  expression  of  tax and  HBZ  mRNA  in  asymptomatic  carriers  (AC)  and  HAM
patients,  and  to investigate  their  association  with  HAM/TSP.
Study  design:  We quantiﬁed  the  expression  of HTLV-1  tax and  HBZ  mRNA  in  37 AC  and 26  HAM patients
classiﬁed  according  to  proviral  load  as  low  (ACL and  HAML: <1%  infected  cells)  or high  (ACH and  HAMH:
>1%).
Results:  The  ACL subgroup  showed  the  lowest  frequency  of individuals  expressing  tax  mRNA  in  compari-
son  with  ACH,  HAML and  HAMH, and  tax mRNA  load  normalized  by proviral  load  was  signiﬁcantly  lower  in
the  ACL. In  turn,  normalized  HBZ  mRNA  expression  was  similar  in all subgroups.  Both  tax and  HBZ  mRNA
expression  were  moderately  correlated  with  proviral  load  in  AC  (r = 0.6,  p <  0.001)  and  were  weaker  in
HAM (r  =  0.4,  p <  0.05).  In contrast,  the  correlation  between  tax and  HBZ  mRNA  load  was  moderate  in  AC
(r =  0.5,  p =  0.001)  and  was much  stronger  in  HAM  (r  =  0.8,  p  < 0.001).  In addition,  HBZ  mRNA  load,  but  not
tax, was  signiﬁcantly  associated  with  motor  disability  in HAM  patients  (p  =  0.036).
Conclusions:  The  expression  of  tax  mRNA  seems  to be best  to estimate  the  risk  of  HAM/TSP,  whereas  HBZ
mRNA  appears  to be a surrogate  marker  to  disease  progression,  indicating  that  they  have  important  but
 pathdistinct roles  in HAM/TSP
. Background
Most individuals infected by human T-lymphotropic virus 1
HTLV-1) will maintain an asymptomatic lifelong infection, but
pproximately 2–5% of infected carriers will develop diseases,
uch as adult T-cell leukemia (ATL),1,2 and HTLV-1-associated
yelopathy/tropical spastic paraparesis (HAM/TSP).3,4 HAM/TSP is
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a chronic inﬂammatory neurodegenerative disease with progres-
sive features leading to motor and sensory disturbances.5
The viral infectivity level in HTLV-1 carriers is quantiﬁed by
the number of infected cells, expressed as the proviral load,
which has been shown to have a wide range in peripheral blood
among infected individuals.6–9 However, the mean proviral load
in patients with ATL, HAM/TSP or other inﬂammatory syndromes
is signiﬁcantly higher than that of healthy carriers,6–9 leading to
the consideration of proviral load as an important risk marker for
HTLV-1-associated diseases.
HTLV-1 tax and HBZ genes code for viral regulatory proteins
that may  promote proliferation of infected cells through the up-
Open access under the Elsevier OA license.regulation of different pathways, contributing to increased proviral
load, and they have close interaction via mutual transcriptional
regulation interference.10–15 HBZ protein is able to suppress Tax-
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f Tax protein.16 Because Tax is the major target of cytotoxic T
ymphocytes, the suppression of Tax expression on the cell sur-
ace is advantageous to the infected cells in evading the immune
esponse.17 In turn, spliced HBZ mRNA transcription is strongly
ependent on the transcription factor Sp1,18 which is ubiquitously
xpressed in infected cells.
Tax protein has been considered the major immunodominant
rotein that induces CTL response,19–22 but recently an HBZ-
peciﬁc CD8+ T cell response was described and suggested to be an
mportant component in restricting proviral load and preventing
AM/TSP development.23,24
In this study, we investigated whether tax and HBZ mRNA
xpression are factors associated with individual variation of provi-
al load in AC and HAM. Then, we evaluated the expression of tax
nd HBZ mRNA in AC and HAM known to have low (<1%) or high
>1%) proviral load.
.1. Objectives
To quantify the expression of tax and HBZ mRNA in asymp-
omatic carriers (AC) and HAM/TSP patients (HAM) showing low
ACL and HAML: <1% infected cells) or high (ACH and HAMH: >1%)
evels of HTLV-1 proviral load, and to investigate the association of
hese parameters with HAM/TSP.
. Study design
.1. Study population
Thirty-seven AC and 26 HAM patients (according to WHO
riteria)25 from Minas Gerais, Brazil were enrolled in this study.
C did not show any clinical abnormalities at neurological clinical
xamination. Spinal cord injury was evaluated for HAM using the
merican Spinal Injury Association (ASIA) impairment scale. ASIA
mpairment scale describes a person’s functional impairment as a
esult of their spinal cord injury. The ASIA scale (impairment calcu-
ation) is: A (Complete): No motor or sensory function in the lowest
acral segment (S4-S5); B (Incomplete): Sensory function below
eurologic level and in S4–S5, no motor function below neurologic
evel; C (Incomplete): Motor function is preserved below neuro-
ogic level, and more than half of the key muscle groups below
eurologic level have a muscle grade < 3; D (Incomplete): Motor
unction is preserved below neurologic level, and at least half of the
ey muscle groups below neurologic level have a muscle grade >3;
 (Normal): Sensory and motor functions are normal. All of the sub-
ects were seronegative for blood-borne pathogens (HIV, HCV, HBV,
hagas disease and syphilis) whose screening tests are mandatory
n Brazilian blood centers and conﬁrmed to be infected by HTLV-1
y Western blot (WB  HTLV 2.4, Genelabs Diagnostics, Singapore) or
eal-time PCR.26 The number of peripheral blood cells infected with
TLV-1 were used in classifying individuals with low (<1%) and high
>1%) proviral loads. This was the best cut-off value for true clas-
iﬁcation of HAM on the GIPH cohort.27 All the individuals did not
se corticosteroid therapy or present parasitic infections detected
y stool examination. The study was approved by the Hemominas
thical Committee.
.2. Quantiﬁcation of HTLV-1 proviral load
DNA was isolated from peripheral blood by column extraction
QIAamp DNA Blood kit; QIAGEN GmbH, Hilden, Germany). The
TLV-1 proviral load was quantiﬁed as previously described.27 The
alue of the proviral load was reported as the number of HTLV-1
opies/104 cells.l Virology 56 (2013) 135– 140
2.3. Quantiﬁcation of tax and HBZ mRNA expression
RNA was  extracted from PBMC using the QIAamp RNA Blood
kit with on-column DNase digestion (QIAGEN GmbH, Hilden,
Germany) and complementary DNA was synthesized from 1 g
RNA using the High-Capacity cDNA Reverse Transcription kit
with random primers (Applied Biosystems, Foster City, USA),
according to the manufacturer’s instructions. The expression
levels of tax mRNA and HBZ mRNA were quantiﬁed by real-time
PCR using serially diluted cDNA (250, 25, 2.5 and 0.25 ng) from
HTLV-1-infected MT2  cells to generate the standard curves and the
GAPDH was  used as reference gene. The ampliﬁcation reaction for
each gene (in separate) was performed using cDNA synthesized
from 250 ng RNA and 1X SYBR Green PCR Master Mix  (Applied
Biosystems, Foster City, USA) in a ﬁnal volume of 25 L with the
following primers: 250 nM Tax-F (5′-CAACACCATGGCCCACTTC-
3′) and Tax-R (5′-CGTACTGGGTATCCGAAAAG-3′) for tax,
300 nM HBZ-F (5′-GACTCAACCGGCGTGGAT-3′) and HBZ-R (5′-
TGACACAGGCAAGCATCGAA-3′) for HBZ splicing isoform, along
with 250 nM hGAPDH-F (5′-ACAGTCAGCCGCATCTTCTT-3′) and
hGAPDH-R (5′-ACGACCAAATCCGTTGACTC-3′) for human GAPDH
(NM 002046.2). Real-time PCR was performed in a ABI Prism 7300
Sequence Detector System (Applied Biosystems, Foster City, USA),
with the following cycle conditions: 2 min  at 50 ◦C and 10 min
at 95 ◦C followed by 45 cycles of 15 s at 95 ◦C and 1 min at 60 ◦C.
Melting curves were performed after the end of the ampliﬁcation
cycles to validate the speciﬁcity of the ampliﬁed products. All
standard dilutions, control and individual samples were run in
duplicate. Quantiﬁcation was accepted when standard curves
had slopes between –3.10 and –3.74, and the r2 was >0.99. The
expression of tax or HBZ mRNA was  calculated by the value of
target gene/value of GAPDH. The viral genes mRNA expression
were normalized by HTLV-1 proviral load, by adjusting with the
level of infected cells.
2.4. Statistical analysis
The Mann–Whitney U test (2-tailed) was used to compare data
between AC and HAM and Kruskal–Wallis among three or more AC
and HAM subgroups. Correlations between continuous variables
(tax mRNA load, HBZ mRNA load, proviral load, age at the onset
of HAM/TSP and duration of disease) were performed using Spear-
man’s rank correlation. A p value <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Expression of tax and HBZ mRNA and HTLV-1 proviral load in
AC and HAM
The HTLV-1 proviral loads for the 37 AC and 26 HAM individ-
uals, classiﬁed into low (L) or high (H) proviral load subgroups are
shown in Fig. 1. Proviral load was  signiﬁcantly different between
each subgroup, except between the ACH vs. HAMH (p = 0.162).
The levels of tax and HBZ mRNA were quantiﬁed in all individual
samples. The expression of tax mRNA was  detected in 14 (37.8%)
AC and in 20 (76.9%) HAM, whereas HBZ mRNA expression was
detected in 32 (86.5%) AC and in all (100%) HAM. Considering clas-
siﬁcation in subgroups according to clinical status and proviral load
level, tax mRNA was detected in 3 (14.3%) of the ACL, 11 (68.8%)
of ACH, 4 (57.1%) of HAML and 16 (84.2%) of HAMH, whereas HBZ
mRNA was  detected in 16 (76.2%) of ACL and in all ACH and HAM
individuals. For all individuals, HBZ mRNA was expressed at a higher
level than tax mRNA, except one carrier in the ACH subgroup, who
showed 3.5-fold higher level of tax mRNA than HBZ mRNA.
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Fig. 1. HTLV-1 proviral load in PBMC sampled from 37 asymptomatic carriers and 26
HAM/TSP patients. The individuals were classiﬁed into AC and HAM subgroups with
low (L: <1%) or high (H: >1%) proviral load. The HTLV-1 proviral load was  signiﬁcantly
different among each subgroup (ACL vs. ACH: p < 0.001, ACL vs. HAML: p = 0.011, ACL
vs. HAMH: p < 0.001, ACH vs. HAML: p < 0.001, HAML vs. HAMH: p < 0.001), except
for  the ACH subgroup vs. the HAMH subgroup (p = 0.162). The solid line indicates 1%






Analysis of the correlation among tax mRNA load, HBZ mRNA load and HTLV-1
proviral load in asymptomatic carriers and HAM/TSP patients.
Individuals mRNA load Correlation with
Proviral load HBZ mRNA load
All (n = 63) Tax r = 0.629; p < 0.001 r = 0.655; p < 0.001
HBZ r = 0.633; p < 0.001 –
AC  (n = 37) Tax r = 0.611; p < 0.001 r = 0.514; p = 0.001
HBZ r = 0.617; p < 0.001 –





statistical differences were calculated with the Mann–Whitney U test.
The HBZ mRNA/DNA ratio was not signiﬁcantly different
etween AC and HAM (p = 0.748), neither among the four sub-
roups. However, the difference in normalized tax mRNA load was
tatistically signiﬁcant between the AC and HAM (p = 0.046), and
ig. 2. HTLV-1 tax and HBZ mRNA expression normalized by HTLV-1-infected cells. (A, B) 
n  tax mRNA normalized by the proviral DNA between AC and HAM patients, but not for
roviral  DNA copies in the subgroups of AC and HAM patients with low (ACL and HAML) or
ifferent between the ACL vs. ACH and ACL vs. HAMH whereas for HBZ mRNA, the expre
hown  as dotted lines. Statistical differences were calculated with the Mann–Whitney U HAM (n = 26) Tax r = 0.459; p = 0.018 r = 0.851; p < 0.001
HBZ r = 0.418; p = 0.034 –
between the ACL vs. ACH (p = 0.008) and ACL vs. HAMH (p = 0.002)
(Fig. 2).
The correlation of tax and HBZ mRNA expression with provi-
ral load was  analyzed (Table 1). The level of tax mRNA showed
moderate correlation with proviral load in all individuals (r = 0.629,
p < 0.001) and in AC (r = 0.611, p < 0.001), but weaker correlation in
HAM (r = 0.459, p = 0.018). Similar results were seen for the cor-
relation between HBZ mRNA load and proviral load in the entire
infected population (r = 0.633, p < 0.001), in AC (r = 0.617, p < 0.001)
and in HAM (r = 0.418; p = 0.034). Thus, HAM patients presented
a weaker correlation of both genes expression and proviral load
in comparison to AC. Likewise, the expression of tax mRNA wasinfected individuals (r = 0.655, p < 0.001), in AC (r = 0.514, p = 0.001),
but much more strongly in HAM patients (r = 0.851, p < 0.001).
Tax and HBZ mRNA load per provirus DNA copies. There was a signiﬁcant difference
 sHBZ mRNA normalized by the proviral DNA. (C, D) Tax and HBZ mRNA load per
 high (ACH and HAMH) proviral load. For tax mRNA, the expression was signiﬁcantly
ssion was  not signiﬁcantly different among the four subgroups. The medians are
test.
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Table 2
Clinical characteristics of HAM/TSP patients and median of tax and HBZ mRNA load normalized by proviral load.
Clinical characteristics Median tax mRNA/pvl p Median HBZ mRNA/pvl p
Neurogenic bladder
Yes (n = 22) 0.00037 0.224 0.190 0.356
No  (n = 4) 0.00140 0.593
Neurogenic intestine
Yes (n = 18) 0.00074 0.276 0.293 0.405
No  (n = 8) 0.00018 0.228
Neuropathic pain
Yes (n = 15) 0.00060 0.456 0.212 0.458
No  (n = 5) 0.00176 0.520
Motor disability
Walk without support (n = 13) 0.00033 306
Need support in walking (n = 9) 0.00087 0.701 169 0.971
Unable to walk (n = 4) 0.00039 293
Motor disability score
ASIA C (n = 6) 0.00075 0.586a 1762 0.036a
ASIA D (n = 19) 0.00049 162







































ttatistical differences were calculated with Mann–Whitney U test or Kruskal–Walli
a Mann–Whitney U test performed by comparison of American Spinal Injury Ass
b Corresponding to value obtained for this unique sample.
.2. High level of HBZ mRNA expression in HAM/TSP patients with
orse motor disability
The expression level of tax and HBZ mRNA was  compared
mong HAM/TSP patients according to their clinical manifestations.
he expression level of tax mRNA normalized by proviral load in
AM did not show statistically signiﬁcant association with spe-
iﬁc clinical symptoms, such as neurogenic bladder dysfunction,
eurogenic intestine, neuropathic pain and functional motor dis-
bility (Table 2). However, the difference in normalized HBZ mRNA
oad, but not in normalized tax mRNA load, was statistically sig-
iﬁcant (p = 0.036) among patients with distinct motor disability
core, being higher in patients with worse degree on the scale of
pinal cord injury (ASIA C vs. ASIA D). There was no signiﬁcant cor-
elation between the age at the onset of HAM/TSP and tax mRNA
oad (r = 0.177, p = 0.402) or HBZ mRNA load (r = −0.159, p = 0.468),
nd neither between the duration of disease and tax mRNA load
r = 0065, p = 0.767) or HBZ mRNA load (r = 0.241, p = 0.268).
. Discussion
HTLV-1 proviral load is considered an important risk marker for
TLV-1-associated diseases, but it is insufﬁcient to determine the
TLV-1 disease outcome.6,27 In this study, we demonstrated that
ax and HBZ mRNA were differentially expressed in HTLV-1 carriers
ccording to their clinical status and proviral load level.
Our results indicate that the infected cells from the ACL sub-
roup were expressing tax mRNA at a very low level, whereas HBZ
RNA was expressed at a similar level to ACH, HAML and HAMH.
he data suggest that the characteristic difference between ACL and
AM patients (with low or high proviral load) was tax mRNA load
nd not HBZ mRNA load. Assuming that tax mRNA levels are propor-
ional to the levels of their corresponding protein,28 these results
re in agreement with a model where Tax plays a major role in HAM
athogenesis by promoting cellular proliferation and inﬁltration of
nfected cells into central nervous system.29 On the other hand,
ax is the main target of the CTL response leading to the lysis of
nfected cell. It was shown that the level of Tax expression and the
evel of lysis of infected cells, as mediated by the CTL response, were
igniﬁcantly and independently associated with HAM/TSP and are
igniﬁcant predictors of proviral load.30,31
ACH individuals represent a group with a high risk to develop
AM/TSP, but there are individuals who will remain healthy
hroughout their lives in spite of high levels of proviral load inn impairment scale: ASIA C vs. D.
peripheral blood.27 Taking into account that the onset of HAM/TSP
is more common in carriers younger than 50 years old,32,33 it was
interesting to observe that the medians of normalized tax and HBZ
mRNA expression were very high in ACH < 55 years old, whereas
both mRNA expression were low in ACH ≥ 55 years old (data not
shown). It is likely that ACH individuals with low expression of
tax and HBZ mRNA should have the highest number of infected
cells with viruses in a latent state, without signiﬁcant expression
of viral genes, and thus present lower risk to develop HAM/TSP, in
spite of the high level of proviral load. Consistent with this hypoth-
esis, proviral integration into areas of the genome characterized
to be transcriptionally active was  signiﬁcantly more frequent in
HAM patients than in AC and in cells expressing Tax than Tax-
negative cells.34,35 In turn, ACH individuals with high levels of tax
and HBZ mRNA expression may  be ineffective at eliminating the
infected cells and are at high risk for developing HAM/TSP or other
HTLV-1-associated diseases.
The differential expression of tax and HBZ mRNA in the sub-
groups indicates that these viral genes may  be independently
regulated, which would indicate that transcriptional control should
not only be dependent on the provirus integration site but also
be HTLV-1 regulated. HBZ mRNA transcription is ubiquitous in
infected cells being dependent of the transcription factor Sp1,18
and agrees with the ﬁnding in this study that there was  no signiﬁ-
cant variation of HBZ mRNA/proviral load in AC and HAM patients.
On the other hand, tax mRNA transcription is up-regulated by the
Tax protein through the 5′-LTR and is down-regulated (transcrip-
tionally or postranscriptionally) by different HTLV-1 proteins, such
as Rex, p30 and HBZ.15,36–38 In our study, there was  a moder-
ate but signiﬁcant correlation between tax and HBZ mRNA load
in AC, which was  much stronger in HAM. It is in contrast what
has been proposed for ATL, whereas HBZ protein is supposed to
have a role in suppressing tax mRNA expression. This strong pos-
itive correlation between tax and HBZ mRNA expression could
be achieved either by the expression of each viral gene in dis-
tinct cellular clones or by up-regulation of Tax expression by HBZ
and vice versa. In agreement with the last possibility, Tax pro-
tein enhances HBZ mRNA transcription,39 and HBZ  mRNA, but not
HBZ protein, indirectly promotes Tax protein expression by down-
regulating the transcription of p30 mRNA.40 Thus, it is possible that
the HTLV-1 regulatory mechanisms controlling the levels of Tax
expression acting in HAM/TSP and ATL pathogenesis include the
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The analysis of tax and HBZ mRNA expression in HAM patients
ccording to their clinical manifestations showed that HBZ mRNA
oad, but not tax mRNA load, was signiﬁcantly higher in HAM with
orse motor disability score, as seen in a previous study.13 Thus,
he data suggest that HBZ could be used as a surrogate marker to
redict HAM/TSP progression, but it is not clear what the role of
BZ in the impairment of motor functions.
In summary, our results emphasize that AC individuals con-
titute a heterogeneous group that should be carefully evaluated
hen compared with HAM/TSP patients. The strong correlation
etween tax and HBZ mRNA load in HAM individuals and their asso-
iation with different aspects of the neurologic disease suggests
hat Tax and HBZ have important but distinct roles in HAM/TSP
athogenesis. Tax may  be critical in disease initiation whereas
BZ may  promote disease progression, resulting in a worse motor
unction. We  conclude that to estimate the risk of HAM/TSP, it is
mportant to evaluate tax mRNA load, rather than only proviral
oad, while HBZ mRNA load might be used to predict the progression
f the disease. How the virus responds to host defense, regulating
ene expression for long-term survival and persistence in infected
ndividuals remains unclear.
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